In 2023, Catalyst Pharmaceuticals will be working to expand the availability of its Lambert-Eaton myasthenic syndrome (LEMS) treatment…
Articles by Marisa Wexler, MS
Teva Pharmaceuticals is seeking authorization from federal regulators in the U.S. to produce and sell a generic version of…
Among those with Lambert-Eaton myasthenic syndrome (LEMS) and other forms of paraneoplastic neurological syndrome, younger patients often experience a…
Catalyst Pharmaceuticals earned $57.2 million in the third quarter of 2022 from sales of Firdapse (amifampridine), its treatment…
Recently updated criteria to identify cancer-associated diseases like Lambert-Eaton myasthenic syndrome (LEMS) are highly specific and sensitive at detecting…
The U.S. Congress has passed five-year extensions for several user fee programs of the U.S. Food and Drug Administration…
The U.S. Food and Drug Administration (FDA) has expanded its approval of Firdapse (amifampridine) to cover pediatric patients, its…
Repeated testing of electrical signaling in muscles before and after exercise is a key test for diagnosing Lambert-Eaton myasthenic…
The prevalence of Lambert-Eaton myasthenic syndrome (LEMS) in Japan is similar to that of other countries, affecting approximately 2.7…
The diagnostic journey of a man in his early 30s with progressive muscle weakness that was ultimately determined to be…